XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration Agreements - Takeda (Details)
3 Months Ended 9 Months Ended 45 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Jan. 31, 2018
program
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Collaboration revenue from customers $ 5,285,000 [1] $ 9,388,000 $ 36,143,000 [1] $ 18,751,000      
Collaborative Arrangement | Takeda Pharmaceutical Company Limited              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Transaction price, change 0   0        
Contract liability 29,200,000   29,200,000   $ 29,200,000 $ 39,800,000  
Number of performance obligations | program             3
Preclinical milestone payment earned not yet received $ 0   $ 0   0    
Collaborative Arrangement | Takeda Pharmaceutical Company Limited | Milestone Triggered              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Collaboration revenue from customers         31,000,000    
Collaborative Arrangement | Takeda Pharmaceutical Company Limited | Product              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Collaboration revenue from customers         $ 0    
Collaborative Arrangement, PTV:PGRN | Takeda Pharmaceutical Company Limited              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Preclinical milestone payment earned not yet received           $ 8,000,000  
[1] Includes related party collaboration revenue from a customer of $0.9 million and $2.5 million for the three and nine months ended September 30, 2021, respectively.